Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: A potential use in intravesical chemotherapy

British Journal of Urology

Volumn 77, Issue 1, 1996, Pages 76-85

  Pu, Y S ^a   Hsieh, T S ^a   Cheng, A L ^a   Tseng, N F ^a   Su, I J ^a   Hsieh, C Y ^a   Lai, M K ^a   Tsai, T C ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bladder neoplasms; Drug resistance; Drug therapy; Tamoxifen; Verapamil

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN P; MITOMYCIN C; RHODAMINE 123; TAMOXIFEN; THIOTEPA; TRANSFORMING GROWTH FACTOR BETA1; VERAPAMIL;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; DRUG RESISTANCE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TISSUE CULTURE CELL;

EID: 0030071752     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1996.82712.x     Document Type: Article

References (29)

1. Soloway MS. Intravesical and systemic chemotherapy in the management of superficial bladder cancer. Ural Clin North Am 1984; 11: 623-35
2. Tsuruo T. lida H. Tsukagoshi S. Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vitro and in vivo through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-72
3. Long Jr JP. Prout Jr GR, Wong YK, Lin CW. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent. J Urol 1990; 143: 1053-6
4. Simpson WG, Tseng MT, Anderson KC, Harty JI. Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells. J Urol 1984; 132: 574-6
5. Yang C-PH, Mellado W. Horwitz SB. Azidopine photoaffmity labeling of multidrug resistance-associated glycoproteins. Biochem Pharmacol 1988: 37: 1417-21
6. Ohi Y, Ohmori H, Shirahama T et al. Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. Cancer Chemother Pharmacol 1992; 30 (suppl): S50-4
7. Park J. Shinohara N. Liebert M. Noto L. Flint A. Grossman HB. P-glycoprotein expression in bladder cancer. J Urol 1994; 151: 43-6
8. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 1989; 7: 803-15
9. Lien EA. Solheim E. Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steadystate treatment. Cancer Res 1991; 51: 4837-44
10. Trump ÜL. Smith DC. Kills PG et al. High-dose oral lamoxifen. a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 1811-6
11. Berman E, Adams M. Duigou-Osterndorf R. Godfrey L. Clarkson B, Andreeff M. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 1991: 77: 818-25
12. Kirk J. Houlbrook S. Stuart NS. Stratford 1J, Harris AL. Carmichael J. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen. toremifen and their metabolites. Ear \Cancer 199 3; 29A: 1152-7
13. Kirk J. Houlbrook S, Stuart NS. Stratford IJ. Harris AL. Carmichael J. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br }Cancer 1993: 67: 1189-95
14. Ramu A, Glaubiger D. Fuks 2. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 1984: 44: 4392-5
15. Yu DS. Yeh MY. Chen SC et al. Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). J Surg Oncol 1988; 37: 177-84
16. Carmichael J. Degraff WG. Gazdar AF. Minna JD, Mitchell }B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42
17. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976; 59: 253-76
18. Chou TC. Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55
19. Chomczynski P. Sacchi N. Single-step met hud of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987: 162: 156-9
20. Höltke HJ. Sagner G. Kassier C. Schmilz G. Sensitive chemiluminescent detection of digoxigenin-labeled nucleic acids: a last and simple protocol and its applications. Kiotech 1992: 12: 104-1 3
21. Lion T, Haas OA. Nonradioactive labeling of probe with digoxigenin by polymerase chain reaction. Anal Biocliem 1990: 188: 335-7
22. Ludescher C, Thaler J. Drach D et al. Detection of activity of P-glycoprotcin in human tumor samples using rhodamine 123. fir ] Haematol 1992: 82: 161-8
23. Kruibbe C. Lippman ME, Wakelield LM et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987: 48: 417-28
24. Massagué ]. Receptors for the TCF- family. Cell 1992: 69: 1067-70
25. Benson AB III. Trump DL, Koeller ]M et al. Phase I study of vinblastine and verapamil given by concurrent i.v. infusion. Cancer Trent Rep 1985; 69: 795-9
26. Shinohara N. Lieber! M. Wedemeyer G. Chang JH, (irossman 1113. Evaluation of multiple drug resistance in human bladder cancer cell lines. J Uwl 199 3; 1 50: 505-9
27. Kimiya K, Niaito S. Soejima T et al. Establishment and characterization of doxoruhicin-resistant human bladder cancer cell line. KK47/ADR. J Urol 1992: 148: 441-5
28. McClay EF. Albright KD. Jones JA. Christen RD. Howell SB. Tamoxil'en modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 1995: 53: 1 571-h
29. 1O Roberts AB. Sporn MB. The transforming growth factor betas. In Sporn MB and Roberts AB eds. Handbook of Experimental Pliamiacohfin. Vol. 95/1. Berlin: SpringerVerlag. 1990: 419-72